<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2101256712
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TRIX 200 mg Capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FENOFIBRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        31.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jordan Sweden Medical and Sterilization Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 513]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI ARABIAN DRUG STORE COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Trix belongs to a group of medicines, commonly known as &#39;fibrates&#39;.</p><p>These medicines are used to lower the level of fats (Lipids) in the blood. For example the fats known as &#39;triglycerides&#39;.</p><p>Trix is used, alongside a low fat diet and other non-medical treatments such as exercise and weight loss, to lower levels of fats in the blood.</p><p>Trix can be used in addition to other medicines (called &#39;statins&#39;) in some circumstances when levels of fats in the blood are not controlled with a statin alone.</p><p>Trix can often also increase the amount of a &#39;good&#39; type of cholesterol, called HDL or high density lipoprotein cholesterol.</p><p>It is always essential to continue a low-fat diet during treatment with Trix.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>A. Do not take Trix if:</p><p>&bull; You are allergic to fenofibrate or any of the other ingredients of this medicine (listed in Section 6)</p><p>&bull; While taking other medicines, you have had an allergic reaction or skin damage from sunlight or UV light (these medicines include other fibrates and an anti-inflammatory medicine called &#39;ketoprofen&#39;)</p><p>&bull; You have severe liver, kidney or gallbladder problems</p><p>&bull; You have pancreatitis (an inflamed pancreas which causes abdominal pain), which is not caused by high levels of fat in the blood</p><p>Do not take Trix if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Trix.</p><p>B. Take special care with Trix:</p><p>Talk to your doctor or pharmacist before taking Trix if:</p><p>&bull; You have any liver or kidney problems.</p><p>&bull; You have an under-active thyroid gland (hypo-thyroidism).</p><p>&bull; You have diabetes, especially Type 2 diabetes that is not well controlled.</p><p>&bull; You have an alcohol problem.</p><p>&bull; You are taking other medicines.</p><p>&bull; You or your family have had muscle problems.</p><p>&bull; You are over 70 years of age.</p><p>(Some of the above conditions can lead to high levels of lipids in your blood and need to be corrected before you start therapy with fenofibrate).</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Trix.</p><p>Your doctor might want to test your blood or urine to check if Trix is working properly and also if your kidneys, muscles and liver are working properly.</p><p>Effects on muscles:</p><p>Contact your doctor quickly if you experience unexplained muscle pain, tenderness or weakness. This is because on rare occasions, there is a risk of muscle problems, which may be serious, including muscle breakdown, which can cause kidney damage. Your doctor may perform a blood test to check the condition of your muscles before and after starting treatment.</p><p>The risk of muscle breakdown is greater in certain patients. Tell your doctor if any of the following applies to you:</p><p>&bull; You have any kidney problems .</p><p>&bull; You have an under active thyroid .</p><p>&bull; You often drink large amounts of alcohol .</p><p>&bull; You have ever had muscle problems during treatment with cholesterol lowering medicines called &ldquo;statins&rdquo; (such as simvastatin, atorvastatin, pravastatin, rosuvastatin or fluvastatin) or fibrates (such as fenofibrate, bezafibrate or gemfibrozil) .</p><p>&bull; You or close family members have a hereditary muscle disorder.</p><p>The risk of muscle problems can be greater if Fenofibrate is taken with cholesterol lowering medicines called &ldquo;statins&rdquo; (such as simvastatin, atorvastatin, pravastatin, rosuvastatin, fluvastatin). Tell your doctor if you are taking any of these medicines.</p><p>&bull;&nbsp; You should avoid drinking alcohol with Fenofibrate as this increases the risk of muscle problems.</p><p>&nbsp;</p><p>C. Taking other medicines:</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>In particular tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&bull; Anti-coagulants to thin your blood (such as warfarin).</p><p>&bull; Other medicines to control fat levels in the blood (such as statins or fibrates). Taking a statin at the same time as Trix may increase the risk of muscle problems.</p><p>&bull; A particular class of medicines to treat diabetes (such as rosiglitazone or pioglitazone).</p><p>&bull; Cyclosporin - used to suppress your immune system.</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Trix.</p><p>D. Taking Trix with food and drink:</p><p>It is important to take the capsule with food - it will not work as well if your stomach is empty.</p><p>E. Pregnancy, breast-feeding and fertility:</p><p>&bull; Do not take Trix and tell your doctor if you are pregnant, think you might be pregnant or are planning to have a baby.</p><p>&bull; Do not take Trix if you are breast-feeding or planning to breastfeed your baby. Ask your doctor or pharmacist for advice before taking any medicine.</p><p>F. Driving and using machines:</p><p>This medicine will not affect you being able to drive or use tools or machines.</p><p>G. Important information about some of the ingredients of Trix:</p><p>Trix contains lactose. If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. You should check with your doctor or pharmacist if you are not sure.</p><p>Taking this medicine:</p><p>&bull; Swallow the capsule whole with a glass of water.</p><p>&bull; Do not open or chew the capsule.</p><p>&bull; Take the capsule with food - it will not work as well if your stomach is empty.</p><p>How much to take:</p><p>The recommended dose for adults is one capsule of Trix 200 mg a day, taken at mealtimes.</p><p>Use in children and adolescents:</p><p>The use of Trix 200mg is not recommended in children under the age of 18.</p><p>People with kidney problems:</p><p>If you have kidney problems, your doctor may tell you to take a lower dose.</p><p>If you take more Trix than you should:</p><p>If you take more Trix than you should or if someone else has taken your medicine, contact your nearest hospital casualty department or tell your doctor immediately.</p><p>If you forget to take Trix:</p><p>&bull; If you forget a dose, take the next dose with your next meal.</p><p>&bull; Then take your next capsule at the normal time.</p><p>&bull; Do not take a double dose to make up for a forgotten dose.</p><p>If you are worried about this talk to your doctor.</p><p>If you stop taking Trix:</p><p>Do not stop taking Trix unless your doctor tells you to, or the capsules make you feel unwell. This is because abnormal levels of fats in the blood need treating for a long period of time.</p><p>Remember that as well as taking Trix it is also important that you:</p><p>&bull; Have a low fat diet.</p><p>&bull; Take regular exercise.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects:</p><p>Stop taking Trix Capsules and see a doctor immediately or go to the casualty department at your nearest hospital if you notice any of the following serious side effects - you may need urgent medical treatment:</p><p>&bull; Allergic reaction &ndash; the signs may include swelling of the face/lips/tongue or throat which may cause difficulty in breathing.</p><p>&bull; Cramps or painful, tender or weak muscles &ndash; these may be signs of muscle inflammation or breakdown which can cause kidney damage or even death.</p><p>&bull; Stomach pain - this may be a sign that your pancreas is inflamed (pancreatitis).</p><p>&bull; Chest pain and feeling breathless &ndash; these may be signs of a blood clot in the lung (pulmonary embolism).</p><p>&bull; Pain, redness or swelling in your leg&ndash; these may be signs of a blood clot in the leg (deep vein thrombosis).</p><p>&bull; Yellowing of the skin and whites of the eyes (jaundice), or an increase in liver enzymes &ndash; these may be signs of an inflamed liver (hepatitis).</p><p>Stop taking Trix Capsules and see a doctor straight away if you notice any of the side effects above.</p><p>Other side effects</p><p>Common (may affect up to 1 in 10 people)</p><p>&bull; Diarrhea.</p><p>&bull; Stomach pain.</p><p>&bull; Wind (flatulence).</p><p>&bull; Feeling sick (nausea).</p><p>&bull; Being sick (vomiting).</p><p>&bull; Raised levels of liver enzymes in the blood &ndash; shown in tests.</p><p>&bull; Increase in homocysteine (too much of this amino acid in the blood has been associated with a higher risk of coronary heart disease, stroke and peripheral vascular disease, although a causal link has not been established).</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>&bull; Headache.</p><p>&bull; Gallstones.</p><p>&bull; Reduced sex drive.</p><p>&bull; Rash, itching or red patches on the skin.</p><p>&bull; Increase in &lsquo;creatinine&rsquo; produced by the kidneys &ndash; shown in tests.</p><p>&bull; Pancreatitis (inflammation of the pancreas leading to abdominal pain).</p><p>&bull; Thromboembolism: pulmonary embolism (blood clot in the lung causing chest pain and breathlessness); deep vein thrombosis (blood clot in the leg causing pain, redness or swelling).</p><p>&bull; Muscle pain, muscle inflammation, muscle cramps and weakness.</p><p>Rare (may affect up to 1 in 10,000 people)</p><p>&bull; Hair loss</p><p>&bull; Increase in &lsquo;urea&rsquo; produced by the kidneys &ndash; shown in tests</p><p>&bull; Increased sensitivity of your skin to sunlight, sun lamps and sunbeds</p><p>&bull; Drop in haemoglobin (that carries oxygen in the blood) and white blood cells &ndash; shown in tests</p><p>&bull; Hepatitis (inflammation of the liver), symptoms of which may be mild jaundice (yellowing of the skin and whites of the eyes), stomach pain and itching</p><p>&bull; Hypersensitivity (allergic reaction) &ndash; signs may include swelling of the face/lips/tongue or throat which may cause difficulty in breathing.</p><p>Not known (frequency cannot be estimated from the available data)</p><p>&bull; Severe form of skin rash with reddening, peeling and swelling of the skin that resembles severe burns</p><p>&bull; Long-term lung problems</p><p>&bull; Muscle breakdown</p><p>&bull; Complications with gallbladder stones</p><p>&bull; Jaundice</p><p>&bull; Feeling exhausted (fatigue)</p><p>&bull; Feeling dizzy (vertigo)</p><p>If you get any unusual breathing discomfort, tell your doctor straight away.</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.</p><p>&bull; Do not use Trix after the expiry date which is stated on the label and carton.</p><p>&bull; This medicinal product does not require any special storage conditions.</p><p>&bull; Do not use any Trix pack that is damaged or shows signs of tampering.</p><p>&bull; Store below 30oC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>contains 200mg of Fenofibrate.</p><p>The other ingredients are: Lactose, Hydroxy propyl methyl cellulose (HPMC), Sodium Lauryl Sulfate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form: Capsules.
Pack size of Trix: 30 Capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>JOSWE-medical</p><p>P.O. Box 851831 Amman 11185 Jordan</p><p>E-mail: joswe@go.com.jo</p><p>www.joswe.com</p><p>Tel: +962 6 5859765, +962 6 5728327</p><p>Fax: +962 6 5814526, +962 6 5728326</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved on 08/2018; Revision number R0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي تريكس لمجموعة من الأدوية تعرف بـ &#39;فينوفايبريت &#39;.</p><p dir="RTL">وتستخدم هذه الأدوية لخفض مستويات الدهون في الدم. مثل الدهون الثلاثية.</p><p dir="RTL">يستخدم تريكس جنبا إلى جنب مع نظام غذائي قليل الدهون وغيره من العلاجات غير الطبية مثل التمارين الرياضية وفقدان الوزن، لتقليل مستويات الدهون في الدم.</p><p dir="RTL">من الممكن استخدام تريكس مع أدوية أخرى (تدعى ستاتين) إذا كانت الستاتين وحدها غير قادرة على التحكم بمستوى الدهون في الدم.</p><p dir="RTL">غالباً ما يعمل تريكس على زيادة كمية الكوليسترول النافع في الدم، المعروف بـ HDL أو ليبوبروتين كوليسترول عالي الكثافة.</p><p dir="RTL">من الضروري الإستمرار باتباع نظام غذائي قليل الدهون خلال فترة العلاج باستخدام تريكس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أ. لا تتناول تريكس إذا:</p><p dir="RTL">&bull; إذا كنت تعاني من حساسية ضد فينوفايبريت أو أي من المكونات الأخرى لهذا الدواء (المذكورة في بند 6).</p><p dir="RTL">&bull; أثناء تناول أدوية أخرى، سببت لديك رد فعل تحسسي أو تلف في الجلد بعد التعرض لأشعة الشمس أو الأشعة فوق البنفسجية (وتشمل هذه الأدوية الفينوفايبريت الأخرى و كيتوبروفين &quot;دواء مضاد للالتهابات&quot;).</p><p dir="RTL">&bull; كنت تعاني من مشاكل حادة في الكبد، الكلى أو المرارة.</p><p dir="RTL">&bull; كنت تعاني من التهاب في البنكرياس (البنكرياس الملتهب المسبب لآلام في البطن)، والتي لم يكن سببها ارتفاع مستويات الدهون في الدم.</p><p dir="RTL">لا تتناول تريكس إذا كان أحد الأمور المذكورة أعلاه ينطبق عليك. إذا كنت غير متأكد، قم بالتحدث إلى الطبيب أو الصيدلاني قبل تناول تريكس.</p><p dir="RTL">ب. أخذ الحيطة والحذر مع تريكس:</p><p dir="RTL">تحدث إلى الطبيب أو الصيدلاني قبل تناول تريكس إذا:</p><p dir="RTL">&bull; كنت تعاني من مشاكل في الكبد أو الكلى.</p><p dir="RTL">&bull; كنت تعاني من خمول في الغدة الدرقية (قصور في الغدة الدرقية).</p><p dir="RTL">&bull; كنت مصاب بداء السكري، وخاصة النوع الثاني الذي لا يمكن السيطرة عليه بشكل جيد.</p><p dir="RTL">&bull; كنت تعاني من مشكلة الكحول.</p><p dir="RTL">&bull; كنت تتناول أدوية أخرى.</p><p dir="RTL">&bull; كنت تعاني أنت أو أحد أفراد العائلة من مشاكل في العضلات.</p><p dir="RTL">&bull; كان عمرك أكثر من 70 سنة.</p><p dir="RTL">(بعض الحالات المذكورة أعلاه قد تؤدي إلى ارتفاع مستويات الدهون في الدم التي يجب تصحيحها قبل بدء العلاج باستخدام فينوفايبريت).</p><p dir="RTL">إذا كان أحد الأمور المذكورة أعلاه ينطبق عليك (أو إذا لم تكن متأكد)، قم بالتواصل مع الطبيب أو الصيدلاني قبل تناول تريكس.</p><p dir="RTL">قد يرغب الطبيب في اجراء فحوصات للدم أو للبول للتحقق مما إذا كان تريكس يعمل بشكل صحيح وأيضا إذا كانت الكليتين والعضلات والكبد تقوم بوظيفتها على أكمل وجه.</p><p dir="RTL">التأثير على العضلات:</p><p dir="RTL">قم بالتواصل مع الطبيب على الفور، إذا كنت تعاني من آلام بالعضلات غير مبررة، تصلب أو ضعف. لأنه في حالات نادرة يكون هناك خطر الإصابة بمشاكل عضلية، وقد تكون خطيرة، وهي تشمل تحلل العضلات، والتي من الممكن أن تسبب تلف الكلى. من الممكن أن يقوم الطبيب بإجراء فحوصات للدم للتأكد من سلامة العضلات قبل وبعد البدء بالعلاج.</p><p dir="RTL">هناك بعض الأشخاص يكونون أكثر عرضة للإصابة بتحلل العضلات. قم بإخبار الطبيب إذا كان أي من الحالات التالية ينطبق عليك:</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل في الكلى.</p><p dir="RTL">&bull; كنت تعاني من قلة نشاط الغدة الدرقية.</p><p dir="RTL">&bull; كنت تتناول كميات كبيرة من الكحول.</p><p dir="RTL">&bull; كنت تعاني من مشاكل عضلية خلال العلاج بأدوية خافضة للكوليسترول تدعى &quot;ستاتين&quot; (مثل سيمفاستاتين، أتورفاستاتين، برافاستاتين، روزوفاستاتين أو فلوفاستاتين) أو فايبريت (مثل فينوفايبريت، بيزافايبريت أو جيمفيبروزيل).</p><p dir="RTL">&bull; كنت أنت أو أحد أفراد عائلتك المقربين يعاني من مشاكل وراثية في العضلات.</p><p dir="RTL">خطر الإصابة بالمشاكل العضلية قد يكون أكبر إذا تم تناول فينوفايبريت مع غيره من الأدوية الخافضة للكوليسترول &quot;ستاتين&quot; (مثل سيمفاستاتين، أتورفاستاتين، برافاستاتين، روزوفاستاتين أو فلوفاستاتين). قم بإخبار الطبيب إذا كنت تتناول أحد هذه الأدوية.</p><p dir="RTL">&bull; يجب الإمتناع عن تناول الكحول مع الفينوفايبريت لأنه يزيد من خطر الإصابة بالمشاكل العضلية.</p><p dir="RTL">ج. تناول أدوية أخرى:</p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلاني إذا كنت تتناول أو تناولت مؤخراً أي أدوية أخرى، بما في ذلك الأدویة التي تم الحصول علیھا بدون وصفة طبیة.</p><p dir="RTL">قم بإخبار الطبيب أو الصيدلاني إذا كنت تتناول أي من الأدوية التالية على وجه الخصوص:</p><p dir="RTL">&bull; مضادات التخثر التي تستخدم لسيولة الدم (مثل الوارفارين).</p><p dir="RTL">&bull; أدوية أخرى للتحكم بمستويات الدهون في الدم (مثل ستاتين أو فايبريت).&nbsp; تناول ستاتين بنفس الوقت مع تريكس من الممكن أن يزيد من خطورة المشاكل العضلية.</p><p dir="RTL">&bull; أنواع معينة من الأدوية التي تستخدم لعلاج داء السكري (مثل روزيجليتازون أو بيوجليتازون).</p><p dir="RTL">&bull; سيكلوسبورين- المستخدم لتثبيط جهاز المناعة.</p><p dir="RTL">إذا كان أحد الأمور المذكورة أعلاه ينطبق عليك (أو إذا لم تكن متأكد)، قم بالتواصل مع الطبيب أو الصيدلاني قبل تناول تريكس.</p><p dir="RTL">د.تناول تريكس مع الطعام والشراب:</p><p dir="RTL">من المهم أن تقوم بتناول كبسولة الدواء مع الطعام- لأنها لن تقوم بوظيفتها إذا تم تناولها على معدة فارغة.</p><p dir="RTL">ه. الحمل، الإرضاع والخصوبة:</p><p dir="RTL">&bull; يجب عليك اخبار الطبيب قبل تناول تريكس إذا كنت حامل أوتعتقدين أنك حامل أو تخططين للإنجاب.</p><p dir="RTL">&bull; إذا كنت مرضع أو تخططين لإرضاع طفلك فلا تقومي بتناول تريكس قبل طلب المشورة من الطبيب أو الصيدلاني.</p><p dir="RTL">و. القيادة واستخدام الآلات:</p><p dir="RTL">لا يؤثر تناول هذا الدواء على ممارسة القيادة أو استخدام الأدوات والآلات.</p><p dir="RTL">ز.معلومات هامة عن بعض مكونات تريكس:</p><p dir="RTL">يحتوي تريكس على اللاكتوز، فإذا أخبرك&nbsp; الطبيب بأنه من الممكن أن لا تتحمل بعض السكريات، قم بالاتصال بالطبيب قبل تناولك لهذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائماً قم بتناول هذا الدواء حسب ارشادات الطبيب أو الصيدلاني. إذا لم تكن متأكداً من كيفية تناوله قم بسؤال الطبيب أو الصيدلاني.</p><p dir="RTL">تناول هذا الدواء:</p><p dir="RTL">&bull; قم ببلع الكبسولة كاملة مع شرب كأس من الماء.</p><p dir="RTL">&bull; لا تقم بفتح الكبسولة أو مضغها.</p><p dir="RTL">&bull; تناول كبسولة الدواء مع الطعام- لأنها لن تقوم بوظيفتها إذا تم تناولها على معدة فارغة.</p><p dir="RTL">الجرعة التي يجب تناولها:</p><p dir="RTL">الجرعة الموصى بها للبالغين هي كبسولة واحدة من تريكس 200 ملغم يومياً، ويتم تناولها في وقت الوجبة.</p><p dir="RTL">الاستخدام من قبل الأطفال والمراهقين.</p><p dir="RTL">لا ينصح باستخدام تريكس 200 ملغم من قبل الأطفال دون سن 18 عام.</p><p dir="RTL">الأشخاص الذين يعانون من مشاكل في الكلى:</p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى، فمن الممكن أن يقوم الطبيب بتخفيض الجرعة.</p><p dir="RTL">إذا تناولت جرعة من تريكس أكثر من اللازم:</p><p dir="RTL">إذا تناولت تريكس أكثر من اللازم أو إذا قام أي شخص آخر بتناوله، قم بالذهاب إلى أقرب مستشفى أو قم باخبار الطبيب على الفور.</p><p dir="RTL">إذا نسيت تناول تريكس:</p><p dir="RTL">&bull; إذا نسيت تناول الجرعة، قم بتناول الجرعة التالية مع الوجبة التالية.</p><p dir="RTL">&bull; وبعد ذلك قم بتناول الكبسولة التالية في وقتها الطبيعي.</p><p dir="RTL">&bull; لا تتناول جرعة مضاعفة لتغطية الجرعة المنسية.</p><p dir="RTL">إذا كنت قلق حيال ذلك قم بالتواصل مع الطبيب.</p><p dir="RTL">إذا توقفت عن تناول تريكس:</p><p dir="RTL">لا تتوقف عن تناول تريكس إلا إذا أخبرك الطبيب بذلك، أو إذا شعرت بتوعك عند تناولك لهذه الكبسولات. وهذا لأن علاج مستويات الدهون غير الطبيعية في الدم قد يحتاج لفترة طويلة.</p><p dir="RTL">تذكر بأنه بالإضافة إلى تناول تريكس فمن الضروري أن:</p><p dir="RTL">&bull; تتبع نظام غذائي قليل الدهون.</p><p dir="RTL">&bull; ممارسة التمارين الرياضية بشكل منتظم.</p><p dir="RTL">إذا كان لديك أي استفسارات أخرى حول استخدام هذا الدواء، قم بسؤال الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، من الممكن أن يسبب هذا الدواء آثار جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">آثار جانبية خطيرة:</p><p dir="RTL">توقف عن تناول كبسولات تريكس وقم بزيارة الطبيب أو قم بالذهاب إلى أقرب مستشفى إذا لاحظت ظهور أي من الآثار الجانبية الخطيرة التالية- من الممكن أن تحتاج إلى علاج طبي عاجل:</p><p dir="RTL">&bull; رد فعل تحسسي- والأعراض قد تشمل انتفاخ في الوجه/ الشفتين/ اللسان أو الحلق والتي من الممكن أن تسبب صعوبة في التنفس.</p><p dir="RTL">&bull; تقلصات أو تصلبات عضلية مؤلمة أو وهن في العضلات- وهذه قد تكون علامات التهاب العضلات أو تحللها، والتي ممكن أن تسبب تلف الكلى أو حتى الموت.</p><p dir="RTL">&bull; ألم في المعدة- وهذه قد تكون أعراض التهاب البنكرياس.</p><p dir="RTL">&bull; ألم في الصدر والشعور بعدم القدرة على التنفس- وهذه قد تكون علامات لتجلط الدم في الرئة ( الانسداد الرئوي).</p><p dir="RTL">&bull; ألم، احمرار أو تورم في الساقين- وهذه قد تكون علامات لتجلط الدم في الساق (تخثر الأوردة العميقة).</p><p dir="RTL">&bull; اصفرار في الجلد وفي الجزء الأبيض من العين (يرقان)، أو زيادة في أنزيمات الكبد- وهذه قد تكون علامات التهاب الكبد.</p><p dir="RTL">توقف عن تناول كبسولات تريكس واذهب إلى الطبيب على الفور، إذا لاحظت ظهور أي من الآثار الجانبية المذكورة أعلاه.</p><p dir="RTL">آثار جانبية أخرى:</p><p dir="RTL">آثار جانبية شائعة (من الممكن أن تصيب لغاية شخص لكل 10 أشخاص)</p><p dir="RTL">&bull; اسهال.</p><p dir="RTL">&bull; ألم في المعدة.</p><p dir="RTL">&bull; ريح (نفخة).</p><p dir="RTL">&bull; الشعور بالمرض (الغثيان).</p><p dir="RTL">&bull; الاستفراغ.</p><p dir="RTL">&bull; زيادة مستويات أنزيمات الكبد في الدم- وهذا يظهر في الفحوصات المخبرية.</p><p dir="RTL">&bull; زيادة الهيموسيستين (ارتبط ارتفاع هذا الحمض الأميني في الدم بارتفاع خطر الإصابة بأمراض القلب التاجية، السكتة الدماغية وأمراض الأوعية الدموية الطرفية، على الرغم من عدم اكتشاف أي رابط سببي بينهم).</p><p dir="RTL">آثار جانبية غير شائعة (من الممكن أن تصيب لغاية شخص لكل 100 شخص)</p><p dir="RTL">&bull; صداع.</p><p dir="RTL">&bull; حصى في المرارة.</p><p dir="RTL">&bull; انخفاض الدافع الجنسي.</p><p dir="RTL">&bull; طفح جلدي، حكة أو بقع حمراء على الجلد.</p><p dir="RTL">&bull; زيادة معدل الكرياتنين الذي تنتجه الكلى- وهذا يظهر في الفحوصات المخبرية.</p><p dir="RTL">&bull; التهاب في البنكرياس مما يسبب آلام في البطن.</p><p dir="RTL">&bull; تخثر في الأوعية الدموية: الانسداد الرئوي (تجلط الدم في الرئة يسبب ألم في الصدر وضيق في التنفس)، تخثر الأوردة العميقة (تجلط الدم في الساق يسبب ألم، احمرار وتورم).</p><p dir="RTL">&bull; ألم في العضلات، التهاب العضلات، تشنج العضلات وضعفها.</p><p dir="RTL">آثار جانبية نادرة (من الممكن أن تصيب لغاية شخص لكل 10,000 شخص)</p><p dir="RTL">&bull; تساقط الشعر.</p><p dir="RTL">&bull; زيادة اليوريا الذي تنتجه الكلى- وهذا يظهر في الفحوصات المخبرية.</p><p dir="RTL">&bull; زيادة حساسية الجلد لأشعة الشمس والإضاءة الشمسية.</p><p dir="RTL">&bull; انخفاض الهيموجلوبين (الذي يحمل الأكسجين في الدم) وخلايا الدم البيضاء- وهذا يظهر في الفحوصات المخبرية.</p><p dir="RTL">&bull; التهاب الكبد، وقد تشمل الأعراض الإصابة بيرقان خفيف ( اصفرار الجلد&nbsp; واصفرار الجزء الأبيض من العين)، ألم في المعدة وحكة.</p><p dir="RTL">&bull; فرط الحساسية (رد فعل تحسسي)- وقد تشمل الأعراض تورم في الوجه/ الشفتين / اللسان أو الحلق والذي من الممكن أن يسبب صعوبة في التنفس.</p><p dir="RTL">آثار جانبية غير معروفة (لا يمكن تقدير معدل تكرار حدوثها من المعلومات المتوفرة)</p><p dir="RTL">&bull; طفح جلدي حاد مع احمرار، تقشير وتورم في الجلد الذي يشبه الحروق الشديدة.</p><p dir="RTL">&bull; مشاكل رئوية طويلة الأمد.</p><p dir="RTL">&bull; تحلل في العضلات.</p><p dir="RTL">&bull; مضاعفات حصى المرارة.</p><p dir="RTL">&bull; اليرقان.</p><p dir="RTL">&bull; الشعور بالإرهاق (التعب).</p><p dir="RTL">&bull; الشعور بالدوار.</p><p dir="RTL">إذا واجهت أي صعوبات غير طبيعية في التنفس، قم بإخبار الطبيب على الفور.</p><p dir="RTL">إذا أصابتك أي آثار جانبية، قم بالتواصل مع الطبيب أو الصيدلاني. وهذه تشمل أي آثار جانبية لم يرد ذكرها في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp; يحفظ بعيداً عن متناول الأطفال.</p><p dir="RTL">&bull; لا تستخدم تريكس بعد انتهاء فترة الصلاحية المذكورة على اللاصق الداخلي و العبوة الخارجية.</p><p dir="RTL">&bull; لا يتطلب هذا المنتج الدوائي أي ظروف تخزين خاصة.</p><p dir="RTL">&bull; لا تستخدم تريكس عند ملاحظة أي علامة تلف عليه.</p><p dir="RTL">&bull; يحفظ بدرجة حرارة أقل من 30 درجة مئوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحتوي على 200 ملغم فينوفايبريت</p><p>المكونات الأخرى هي: لاكتوز، هيدروكسي بروبيل ميثيل سيللولوز (HPMC) ، صوديوم لوريل سالفيت.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشكل الصيدلاني: كبسولات</p><p>حجم عبوة تريكس: 30 كبسولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة الأردنية السويدية للمنتجات الطبية و التعقيم.</p><p dir="RTL">صندوق بريد 851831&nbsp; عمان 11185&nbsp; الأردن</p><p dir="RTL">الايميل: joswe@go.com.jo</p><p dir="RTL">www.joswe.com</p><p dir="RTL">هاتف:&nbsp; 5859765 6 +962 ، 5728327 6 +962</p><p dir="RTL">فاكس:&nbsp; 5814526 6 +962 ، 5728326 6 +962</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تمت مراجعة هذه النشرة في  08/2018 ؛ رقم المراجعة R0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Trigless ® 200 mg Capsules.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 200 mg fenofibrate.
Excipients with known effect: lactose monohydrate
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsule
Trigless 200mg: Hard gelatin capsule with white body and purple cap filled with White to off white powder
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trigless &reg; 200mg is&nbsp;indicated as&nbsp;an adjunct to diet and other non-pharmacological treatment</p><p>(e.g. exercise, weight reduction)&nbsp;for the following:</p><p>- Treatment of severe hypertriglyceridaemia with or without low HDL cholesterol.</p><p>- Mixed hyperlipidaemia&nbsp;when a statin is&nbsp;contraindicated or not tolerated.</p><p>- Mixed hyperlipidaemia in patients at high cardiovascular risk in addition to a statin when&nbsp;triglycerides and HDL&nbsp;cholesterol are not adequately controlled.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dietary measures initiated before therapy should be continued. Response to therapy should be monitored by determination of serum lipid values. If an adequate response has not been&nbsp;achieved after several months (e.g. 3 months), complementary or different therapeutic measures should be considered.</p><p>Posology:</p><p>Adults:</p><p>The recommended dose is 200mg daily administered as one capsule of Fenofibrate 200mg. The dose can be titrated up to 267 mg daily administered as one capsule of fenofibrate 267mg or 4 capsules of finofibrate 67mg, if required. This maximum dose is not recommended in addition to a statin.</p><p>Special populations</p><p>Geriatric population:</p><p>In elderly patients, without renal impairment, the usual adult dose is recommended. Renal Impairment: Dosage reduction is required in patients with renal impairment. In mild to moderate chronic kidney disease, start with one capsule of 67 mg micronised fenofibrate once daily. In patients with severe chronic kidney disease, fenofibrate is not recommended.</p><p>Hepatic impairment:</p><p>Trigless &reg; 200mg is not recommended for use in patients with hepatic impairment due to the lack of data.</p><p>Paediatric population:</p><p>The safety and efficacy of fenofibrate in children and adolescents younger than 18 years has not been established. No data are available. Therefore, the use of fenofibrate is not recommended in paediatric subjects under 18 years.</p><p>Method of administration:</p><p>Capsules should be swallowed whole during a meal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -Hepatic insufficiency (including biliary cirrhosis and unexplained persistent liver function abnormality, 
-Known gallbladder disease, 
-Severe renal dysfunction, 
-Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridemia, 
-Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen, 
-Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Secondary causes of hyperlipidemia:</p><p>Secondary causes of hyperlipidemia, such as uncontrolled type 2 diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease, pharmacological treatment, alcoholism, should be adequately treated before fenofibrate therapy is considered. Secondary cause of hypercholesterolemia related to pharmacological treatment can be seen with diuretics, &beta;-blocking agents, estrogens, progestogens, combined oral contraceptives, immunosuppressive agents and protease inhibitors. In these cases it should be ascertained whether the hyperlipidaemia is of primary or secondary nature (possible elevation of lipid values caused by these therapeutic agents).</p><p>Liver function:</p><p>As with other lipid lowering agents, increases have been reported in transaminase levels in some patients. In the majority of cases these elevations were transient, minor and asymptomatic. It is recommended that transaminase levels are monitored every 3 months during the first 12 months of treatment and thereafter periodically. Attention should be paid to patients who develop increase in transaminase levels and therapy should be discontinued if AST (SGOT) and ALT (SGPT) levels increase to more than 3 times the upper limit of the normal range. When symptoms indicative of hepatitis occur (e.g. jaundice, pruritus), and diagnosis is confirmed by laboratory testing, fenofibrate therapy should be discontinued.</p><p>Pancreas:</p><p>Pancreatitis has been reported in patients taking fenofibrate (see sections 4.3 and 4.8). This&nbsp;occurrence may represent a failure of efficacy in patients with severe hypertriglyceridaemia, a&nbsp;direct drug effect,&nbsp;or a secondary&nbsp;phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct.</p><p>Muscle:</p><p>Muscle toxicity, including rare cases of rhabdomyolysis, with or without renal failure has been reported with administration of fibrates and other lipid-lowering agents. The incidence of this disorder increases in cases of hypoalbuminaemia and previous renal insufficiency. Patients with pre-disposing factors for myopathy and/or rhabdomyolysis, including age above 70 years, personal or familial history of hereditary muscular disorders, renal impairment, hypothyroidism and high alcohol intake, may be at an increased risk of developing rhabdomyolysis. For these patients, the putative benefits and risks of fenofibrate therapy should be carefully weighed up.</p><p>Muscle toxicity should be suspected in patients presenting diffuse myalgia, myositis, muscular cramps and weakness and/or marked increases in CPK (levels exceeding 5 times the normal range). In such cases treatment with fenofibrate should be stopped.</p><p>The risk of muscle toxicity may be increased if the drug is administered with another fibrate or an HMG-CoA reductase inhibitor, especially in cases of pre-existing muscular disease. Consequently, the co-prescription of fenofibrate with a HMG-CoA reductase inhibitor or another fibrate should be reserved to patients with severe combined dyslipidaemia and high cardiovascular risk without any history of muscular disease and a close monitoring of potential muscle toxicity.</p><p>Renal function:</p><p>Treatment should be interrupted in case of an increase in creatinine levels &gt; 50% ULN (upper limit of normal). It is recommended that creatinine is measured during the first three months after initiation of treatment and thereafter periodically (for dose recommendations, see section 4.2).</p><p>Excipients:</p><p>As this medicinal product contains Lactose, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Oral Anti-coagulants</p><p>Fenofibrate enhances oral anti-coagulant effect and may increase risk of bleeding. In patients receiving oral anti-coagulant therapy, the dose of anti-coagulant should be reduced by about one-third at the commencement of treatment and then gradually adjusted if necessary according to INR (International Normalised Ratio) monitoring.</p><p>Cyclosporin</p><p>Some severe cases of reversible renal function impairment have been reported during concomitant administration of fenofibrate and cyclosporin. The renal function of these patients&nbsp;must therefore be closely monitored and the treatment with fenofibrate stopped in the case of severe alteration of laboratory parameters.</p><p>HMG-CoA reductase inhibitors or Other Fibrates</p><p>The risk of serious muscle toxicity is increased if a fibrate is used concomitantly with HMG-CoA reductase inhibitors or other fibrates. Such combination therapy should be used with caution and patients monitored closely for signs of muscle toxicity (see section 4.4.). There is currently no evidence to suggest that fenofibrate affects the pharmacokinetics of simvastatin.</p><p>Glitazones</p><p>Some cases of reversible paradoxical reduction of HDL-cholesterol have been reported during concomitant administration of fenofibrate and glitazones. Therefore it is recommended to monitor HDL-cholesterol if one of these components is added to the other and stopping of either therapy if HDL-cholesterol is too low.</p><p>Cytochrome P450 enzymes</p><p>In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C19 and CYP2A6, and mild-to-moderate of CYP2C9 at therapeutic concentrations.</p><p>Patients co-administered fenofibrate and CYP2C19, CYP2A6, and especially CYP2C9 metabolised drugs with a narrow therapeutic index should be carefully monitored and, if necessary, dose adjustment of these drugs is recommended.</p><p>Other</p><p>In common with other fibrates, fenofibrate induces microsomal mixed-function oxidases involved in fatty acid metabolism in rodents and may interact with drugs metabolised by these enzymes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy: There are no adequate data from the use of fenofibrate in pregnant women. Animal studies have not demonstrated any teratogenic effects. Embryotoxic effects have been shown at doses in the range of maternal toxicity (see section 5.3). The potential risk for humans is unknown. Therefore, Trigless &reg; 200mg should only be used during pregnancy after a careful benefit/risk assessment.</p><p>Lactation: It is unknown whether fenofibrate and/or its metabolites are excreted in human milk. A risk to the suckling child cannot be excluded. Therefore fenofibrate should not be used during breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Trigless &reg; 200mg has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported ADRs during Fenofibarte therapy are digestive, gastric or intestinal disorders.</p><p>The following undesirable effects have been observed during placebo-controlled clinical trials (n=2344) with the below indicated frequencies:</p><table border="1" cellspacing="1" cellpadding="1" style="width:715px"><tbody><tr><td style="width:200px">MedDRA system organ class</td><td style="width:114px">Common<br />&gt;1/100, &lt;1/10</td><td style="width:125px">Uncommon<br />&gt;1/1,000, &lt;1/100</td><td style="width:142px">Rare<br />&gt;1/10,000, &lt;1/1,000</td><td style="width:136px"><p>Very rare<br />&lt;1/10,000 incl.</p><p>isolated reports</p></td></tr><tr><td style="width:200px">Blood and lymphatic system disorders</td><td style="width:114px">&nbsp;</td><td style="width:125px">&nbsp;</td><td style="width:142px">Haemoglobin decreased<br />White blood cell count decreased</td><td style="width:136px">&nbsp;</td></tr><tr><td style="width:200px">Immune system disorders</td><td style="width:114px">&nbsp;</td><td style="width:125px">&nbsp;</td><td style="width:142px">Hypersensitivity</td><td style="width:136px">&nbsp;</td></tr><tr><td style="width:200px">Nervous system disorders</td><td style="width:114px">&nbsp;</td><td style="width:125px">Headache</td><td style="width:142px">&nbsp;</td><td style="width:136px">&nbsp;</td></tr><tr><td style="width:200px">Vascular disorders</td><td style="width:114px">&nbsp;</td><td style="width:125px">Thromboembolism (pulmonary embolism, deep vein thrombosis)*</td><td style="width:142px">&nbsp;</td><td style="width:136px">&nbsp;</td></tr><tr><td style="width:200px">Gastrointestinal diorders</td><td style="width:114px">Gastrointestinal signs and symptoms (abdominal pain, nausea, vomiting, diarrhoea, flatulence)</td><td style="width:125px">Pancreatitis*</td><td style="width:142px">&nbsp;</td><td style="width:136px">&nbsp;</td></tr><tr><td style="width:200px">Hepatobiliary disorders</td><td style="width:114px">Transaminases increased (see section 4.4)</td><td style="width:125px">Cholelithiasis (see section 4.4)</td><td style="width:142px">Hepatitis</td><td style="width:136px">&nbsp;</td></tr><tr><td style="width:200px">Skin and subcutaneous tissue disorders</td><td style="width:114px">&nbsp;</td><td style="width:125px">Cutaneous hypersensitivity (e.g. Rashes, pruritus, urticaria)</td><td style="width:142px">Alopecia<br />Photosensitivity reactions</td><td style="width:136px">&nbsp;</td></tr><tr><td style="width:200px">Musculoskeletal, connective tissue and bone disorders</td><td style="width:114px">&nbsp;</td><td style="width:125px">Muscle disorder (e.g. myalgia, myositis, muscular spasms and&nbsp;weakness)</td><td style="width:142px">&nbsp;</td><td style="width:136px">&nbsp;</td></tr><tr><td style="width:200px">Reproductive system and breast disorders</td><td style="width:114px">&nbsp;</td><td style="width:125px">Sexual dysfunction</td><td style="width:142px">&nbsp;</td><td style="width:136px">&nbsp;</td></tr><tr><td style="width:200px">Investigations</td><td style="width:114px">&nbsp;</td><td style="width:125px">Blood creatinine increased</td><td style="width:142px">Blood urea increased</td><td style="width:136px">&nbsp;</td></tr></tbody></table><p>* In the FIELD-study, a randomized placebo-controlled trial performed in 9795 patients with type 2 diabetes mellitus, a statistically significant increase in pancreatitis cases was observed in patients receiving fenofibrate versus patients receiving placebo (0.8% versus 0.5%; p = 0.031).</p><p>In the same study, a statistically significant increase was reported in the incidence of pulmonary embolism (0.7% in the placebo group versus 1.1% in the fenofibrate group; p = 0.022) and a statistically non-significant increase in deep vein thromboses (placebo: 1.0 % [48/4900 patients] versus fenofibrate 1.4% [67/4895 patients]; p = 0.074).</p><p>In addition to those events reported during clinical trials, the following side effects have been reported spontaneously during postmarketing use of Fenofibrate. A precise frequency cannot be estimated from the available data and is therefore classified as &ldquo;not known&rdquo;.</p><p>-Respiratory, thoracic and mediastinal disorders: Interstitial lung disease.</p><p>- Musculoskeletal, connective tissue and bone disorders: Rhabdomyolysis.</p><p>- Hepatobiliary disorders: jaundice, complications of cholelithiasis (e.g. cholecystitis, cholangitis, biliary colic)</p><p>- Fatigue</p><p>- Vertigo</p><p>- Skin and Subcutaneous Tissue Disorders: severe cutaneous reactions (e.g erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis)</p><p>-To reports any side effect (s):</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Only anecdotal cases of fenofibrate overdosage have been received. In the majority of cases no overdose symptoms were reported.</p><p>No specific antidote is known. If overdose is suspected, treat symptomatically and institute appropriate supportive measures as required. Fenofibrate cannot be eliminated by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Serum Lipid Reducing Agents/Cholesterol and Triglyceride Reducers/Fibrates. ATC code: C10 AB 05.</p><p>Trigless &reg; 200mg is a formulation containing 200mg of micronised fenofibrate; the administration of this product results in effective plasma concentrations identical to those obtained with 3 capsules of Fenofibrate 67 mg.</p><p>Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type &alpha; (PPAR&alpha;).</p><p>Through activation of PPAR&alpha;, fenofibrate increases lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production&nbsp;of Apoprotein C-III.&nbsp;Activation of PPAR&alpha;&nbsp;also induces an increase in the synthesis of&nbsp;Apoproteins A-I, and A-II.</p><p>There is evidence that treatment with fibrates may reduce coronary heart disease events but they have not been shown to decrease all cause mortality in the primary or secondary prevention of cardiovascular disease.</p><p>The Action to Control Cardiovascular Risk in Diabetes (ACCORD) lipid trial was a randomized placebo-controlled study of 5518 patients with type 2 diabetes mellitus treated with fenofibrate in addition to simvastatin. Fenofibrate plus simvastatin therapy did not show any significant differences compared to simvastatin monotherapy in the composite primary&nbsp;outcome of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death (hazard ratio [HR] 0.92, 95% CI 0.79-1.08, p = 0.32; absolute risk reduction: 0.74%). In the pre-specified subgroup of dyslipidaemic patients, defined as those in the lowest tertile of HDL-C&nbsp;(&le;34 mg/dl or 0.88 mmol/L) and highest tertile of TG (&ge;204 mg/dl or 2.3 mmol/L) at baseline, fenofibrate plus simvastatin therapy demonstrated a 31% relative reduction compared to simvastatin monotherapy for the composite primary outcome (hazard ratio [HR] 0.69, 95% CI&nbsp;0.49-0.97, p = 0.03; absolute risk reduction: 4.95%). Another prespecified subgroup analysis&nbsp;identified a statistically significant treatment-by-gender interaction (p = 0.01) indicating a possible treatment benefit of combination therapy in men (p=0.037) but a potentially higher&nbsp;risk for the primary outcome in women treated with combination therapy compared to simvastatin monotherapy (p=0.069). This was not observed in the aforementioned subgroup of&nbsp;patients with dyslipidaemia but there was also no clear evidence of benefit in dyslipidaemic women treated with fenofibrate plus simvastatin, and a possible harmful effect in this subgroup could not be excluded.</p><p>Studies with fenofibrate on lipoprotein fractions show decreases in levels of LDL and VLDL cholesterol. HDL cholesterol levels are frequently increased. LDL and VLDL triglycerides are reduced. The overall effect is a decrease in the ratio of low and very low density lipoproteins to high density lipoproteins, which epidemiological studies have correlated with a decrease in atherogenic risk. Apolipoprotein-A and apolipoprotein-B levels are altered in parallel with HDL and LDL and VLDL levels respectively.</p><p>Extravascular deposits of cholesterol (tendinous and tuberous xanthoma) may be markedly reduced or even entirely eliminated during fenofibrate therapy. Plasma uric acid levels are increased in approximately 20% of hyperlipidaemic patients, particularly in those with type IV disease.</p><p>Patients with raised levels of fibrinogen treated with fenofibrate have shown significant reductions in this parameter, as have those with raised levels of Lp(a). Other inflammatory markers such as C Reactive Protein are reduced with fenofibrate treatment.</p><p>The uricosuric effect of fenofibrate leading to reduction in uric acid levels of approximately 25% should be of additional benefit in those dyslipidaemic patients with hyperuricaemia. Fenofibrate has been shown to possess an anti-aggregatory effect on platelets in animals and in a clinical study, which showed a reduction in platelet aggregation induced by ADP, arachidonic acid and epinephrine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption:</p><p>Maximum plasma concentrations (Cmax) occur within 4 to 5 hours after oral administration. Plasma concentrations are stable during continuous treatment in any given individual. The absorption of fenofibrate is increased when administered with food.</p><p>Distribution:</p><p>Fenofibric acid is strongly bound to plasma albumin (more than 99%).</p><p>Metabolism and excretion:</p><p>After oral administration, fenofibrate is rapidly hydrolised by esterases to the active metabolite fenofibric acid.</p><p>No unchanged fenofibrate can be detected in the plasma. Fenofibrate is not a substrate for CYP 3A4. No hepatic microsomal metabolism is involved. The drug is excreted mainly in the urine. Practically all the drug is eliminated within 6 days. Fenofibrate is mainly excreted in the form of fenofibric acid and its glucuronoconjugate. In elderly patients, the fenofibric acid apparent total plasma clearance is not modified. Kinetic studies following the administration of a single dose and continuous treatment have demonstrated that the drug does not accumulate.</p><p>Fenofibric acid is not eliminated during haemodialysis.</p><p>The plasma elimination half-life of fenofibric acid is approximately 20 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Chronic toxicity studies have yielded no relevant information about specific toxicity of fenofibrate.</p><p>Studies on mutagenicity of fenofibrate have been negative. In rats and mice, liver tumours have been found at high dosages, which are attributable to peroxisome proliferation. These changes are specific to small rodents and have not been observed in other animal species. This is of no relevance to therapeutic use in man. Studies in mice, rats and rabbits did not reveal any teratogenic effect. Embryotoxic effects were observed at doses in the range of maternal toxicity. Prolongation of the gestation period and difficulties during delivery were observed at high doses. No sign of any effect on fertility has been detected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose</p><p>Hydroxy propyl methyl cellulose (HPMC)</p><p>Sodium Lauryl Sulfate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVDC/ PVC with Aluminium foil blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jordan Sweden Medical and Sterilization
Joswe-medical
P.O. Box 851831 Amman 11185 Jordan
E-mail: joswe@go.com.jo
www.joswe.com
Tel: +962 6 5859765, +962 6 5728327
Fax: +962 6 5814526, +962 6 5728326
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                16th March 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>